Overview

Phase I Study to Compare the Safety, Pharmacokinetic Profiles of CJ Amlodipine/Valsartan 10/160mg and Novartis Exforge 10/160mg

Status:
Completed

Trial end date:
2012-04-01

Target enrollment:

Participant gender:

Summary

The objectives of this study are: - To compare the safety profile of CJ Amlodipine/Valsartan 10/160mg and Novartis Exforge 10/160mg after a single oral administration in healthy male volunteers - To compare the pharmacokinetic profile of CJ Amlodipine/Valsartan 10/160mg and Novartis Exforge 10/160mg after a single oral administration in healthy male volunteers

Phase:

Phase 1

Details

Lead Sponsor:

CJ HealthCare Corporation
HK inno.N Corporation

Treatments:

Amlodipine
Amlodipine, Valsartan Drug Combination
Lactitol
Valsartan